Dianthus Therapeutics reported financial results for the quarter ended June 30, 2026. The company incurred a net loss of $50.2 million, or $0.90 per share, compared to a $31.6 million loss in the prior year period. Research and development expenses rose to $48.7 million from $26.3 million, driven by higher clinical costs for claseprubart. General and administrative expenses increased to $13.6 million from $8.9 million due to headcount growth. The company held approximately $1.2 billion in cash as of June 30, 2026, providing runway into 2030. Clinically, the Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis initiated in June with top-line results expected in late 2028. Interim data from the Phase 3 CAPTIVATE trial in CIDP showed a 75% response rate in the first 40 participants, and enrollment for the Phase 2 MoMeNtum trial in MMN was completed ahead of schedule. Dianthus Therapeutics is a clinical-stage biotechnology company developing therapies for severe autoimmune diseases.

Dianthus Therapeutics, Inc. released an updated corporate presentation containing interim responder analysis data for the first 40 patients who completed Part A of the Phase 3 CAPTIVATE trial of claseprubart in chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for inflammatory and inflammatory-related diseases.